A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.
| Autor: | Vijai J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Topka S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Villano D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Ravichandran V; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Maxwell KN; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Maria A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Thomas T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Gaddam P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering, New York, New York., Lincoln A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering, New York, New York., Kazzaz S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Wenz B; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Carmi S; Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel., Schrader KA; British Columbia Cancer Agency, Canada's Michael Smith Genome Sciences Centre, Vancouver, Canada., Hart SN; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota., Lipkin SM; Department of Medicine, Weill Cornell Medical College, New York, New York., Neuhausen SL; Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California., Walsh MF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering, New York, New York.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Zhang L; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Lejbkowicz F; Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B Rappaport Faculty of Medicine, Haifa, Israel., Rennert H; Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B Rappaport Faculty of Medicine, Haifa, Israel., Stadler ZK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Robson M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Weitzel JN; Clinical Cancer Genetics (for the City of Hope Clinical Cancer Genetics Community Research Network), City of Hope, Duarte, California., Domchek S; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.; Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Daly MJ; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts.; Center for Human Genetic Research and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts., Couch FJ; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.; Department of Laboratory Medicine and Pathology, and Health Sciences Research, Mayo Clinic, Rochester, Minnesota., Nathanson KL; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.; Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.; Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania., Norton L; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Rennert G; Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B Rappaport Faculty of Medicine, Haifa, Israel., Offit K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. offitk@mskcc.org.; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer discovery [Cancer Discov] 2016 Nov; Vol. 6 (11), pp. 1267-1275. Date of Electronic Publication: 2016 Sep 21. |
| DOI: | 10.1158/2159-8290.CD-16-0487 |
| Abstrakt: | Known gene mutations account for approximately 50% of the hereditary risk for breast cancer. Moderate and low penetrance variants, discovered by genomic approaches, account for an as-yet-unknown proportion of the remaining heritability. A truncating mutation c.325C>T:p.Arg109* (R109X) in the ATP-dependent helicase ERCC3 was observed recurrently among exomes sequenced in BRCA wild-type, breast cancer-affected individuals of Ashkenazi Jewish ancestry. Modeling of the mutation in ERCC3-deficient or CRISPR/Cas9-edited cell lines showed a consistent pattern of reduced expression of the protein and concomitant hypomorphic functionality when challenged with UVC exposure or treatment with the DNA alkylating agent IlludinS. Overexpressing the mutant protein in ERCC3-deficient cells only partially rescued their DNA repair-deficient phenotype. Comparison of frequency of this recurrent mutation in over 6,500 chromosomes of breast cancer cases and 6,800 Ashkenazi controls showed significant association with breast cancer risk (OR Significance: A functionally significant recurrent ERCC3 mutation increased the risk for breast cancer in a genetic isolate. Mutated cell lines showed lower survival after in vitro exposure to DNA-damaging agents. Thus, similar to tumors arising in the background of homologous repair defects, mutations in nucleotide excision repair genes such as ERCC3 could constitute potential therapeutic targets in a subset of hereditary breast cancers. Cancer Discov; 6(11); 1267-75. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 1197. (©2016 American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|